Loading news...
On Monday, Wave Life Sciences Ltd. (NASDAQ: WVE) said it regained full rights to WVE-006 from GSK Plc (NYSE: GSK).
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address both lung and liver manifestations of this disease
Emerald Advisers LLC lowered its position in shares of WAVE Life Sciences Ltd. (NASDAQ: WVE) by 8.0% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 2,996,900 shares of the company's stock after selling 260,219 shares during the period. Emerald Advisers LLC owned 1.88% of WAVE
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 9 of this series includes Target Corp., The Trade Desk, UFP Technologies, Verizon, and Williams Companies.
Adrian Rawcliffe disposed of 42,000 shares for a total transaction value of ~$630,000 on Dec. 8, 2025. This transaction was derivative-based, involving the exercise and immediate sale of options; all activity was through direct ownership with no indirect entities involved.
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.
Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026
WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report)'s stock price was down 4.5% during trading on Friday. The company traded as low as $14.22 and last traded at $14.17. Approximately 1,422,050 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 5,529,458 shares. The stock had previously
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET.
In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.
A surge of 147% in a single session is an unusual occurrence in biotech — and nearly unprecedented for a company that has spent years trading discreetly under the radar. However, that is precisely what transpired with Wave Life Sciences (NASDAQ:WVE), the RNA-focused drug developer that astonished Wall Street with data so unexpectedly robust that it reshaped the company's future in just a few hours.
Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.
The golden cross is a highly accurate and bullish technical signal that investors can use to find stocks that can make good momentum trades. A golden cross pattern forms when a stock's 50-day moving average crosses above its 200-day moving average.
CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of $19.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 2,631,578 ordinary shares at an offering price of $18.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.
It wasn't hard to be optimistic about the biotech's future, given its excellent news from the lab on Monday. Prognosticators fell over themselves publishing bullish new takes on the company the following day.
Wave Life Sciences Ltd. (NASDAQ: WVE) stock rose Tuesday on continued optimism after the company announced data from the lowest therapeutic cohort of the ongoing INLIGHT trial of WVE-007 for weight loss.
The biotech's investigational weight loss drug did very well in a clinical trial. This is a white-hot segment of the pharmaceutical market, so it's little wonder investors subsequently pounced on the stock.
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms and conditions. All of the securities in the offering will be sold by Wave Life Sciences.
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript